$SGRY

Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.

Surgery Partners (SGRY) reported Q2 revenue of $848.9M versus $830.7M estimates and adjusted EPS of $0.10 versus $0.06, with adjusted EBITDA of $125.2M slightly above estimates. Management cited higher-acuity procedure growth and payer mix shift toward government reimbursement. Full-year revenue guidance was reconfirmed at $3.4B midpoint.

The article highlights Q2 results for outpatient and specialty care firms. Surgery Partners (SGRY) reported slowest revenue growth and weaker full-year guidance, with the stock down 1.4% to $15.32. LifeStance (LFST) revenue rose to $435.4M (+26.1%) and shares rose 18.3% to $12.27. U.S. Physical Therapy (USPH) revenue $214.1M (+8.5%) and shares $81.96. Encompass Health (EHC) revenue $1.60B (+9.6%) and shares $124.69. agilon health (AGL) revenue $1.49B (+7.2%), shares $87.56.

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.

Surgery Partners, Inc. (SGRY) reported Q2 results that exceeded expectations, citing revenue and adjusted EBITDA growth from higher acuity procedures and physician recruitment. The company said a pending Idaho Falls divestiture will simplify operations, reduce leverage, and focus on core short-stay surgical facilities. Full-year guidance was reaffirmed, with updated outlook after the sale closes.

Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.

Surgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.

Surgery Partners (NASDAQ: SGRY) reported Q2 CY2026 revenue of $848.9 million, up 2.7% year over year, beating Wall Street’s estimate by 2.2%. The company forecast full-year revenue around $3.4 billion. Non-GAAP EPS was $0.10, clearing consensus, and full-year EPS is expected to rise from $0.32 to $0.56.

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 SURGERY PARTNERS, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE BRENTWOOD, Tenn., August 10, 2026 (GLOBE NEWSWIRE) - Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or t